{"id":"W3080988574","doi":"10.1200/jco.20.01164","title":"MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":153,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Cycle for Survival; Ovarian Cancer Research Fund Alliance; Array BioPharma; Memorial Sloan-Kettering Cancer Center; Pfizer; Ovarian Cancer Research Fund","keywords":"Medicine; Hazard ratio; Chemotherapy; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; KRAS; Serous fluid; Chemotherapy regimen; Surgery; Gastroenterology; Randomized controlled trial; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001779624,0.0006746945,0.001486531,0.0004957485,0.0002075183,0.0006604604,0.0004850874,0.0009188933,0.003859043],"category_scores_gemma":[0.001447567,0.0003773668,0.0009961914,0.0002744353,0.0006955336,0.000752844,0.0003672092,0.001822014,0.0003568939],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000761035,"about_ca_system_score_gemma":0.0006408317,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005287701,"about_ca_topic_score_gemma":0.001806315,"domain_scores_codex":[0.9992691,0.0004199322,0.00004507314,0.00009555773,0.0000581893,0.0001123146],"domain_scores_gemma":[0.9992433,0.0002819566,0.0001854566,0.00004414448,0.00002470662,0.0002205288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9452481,0.006817432,0.002178231,0.0003501076,0.000519811,0.00003148479,0.00005653071,0.0008765568,0.003390905,0.0001785278,0.0004567737,0.03989548],"study_design_scores_gemma":[0.5442632,0.4358205,0.009452946,0.0001016614,0.001069213,0.0001225631,0.00007004623,0.003029482,0.003389827,0.0004868492,0.002158082,0.00003552629],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994064,0.002364736,0.0003555594,0.0002879724,0.0001799945,0.0009159685,0.0002889638,0.0000477048,0.001495041],"genre_scores_gemma":[0.9968284,0.0006592077,0.0005166463,0.0002445962,0.0000926997,0.0005336479,0.0001708722,0.000005622872,0.0009483161],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003859043,"threshold_uncertainty_score":0.01290977,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1873591823960311,"score_gpt":0.4321359889363601,"score_spread":0.244776806540329,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}